Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.


CSE:MDMA - Post by User

Post by inviolablspiriton Jan 02, 2025 3:34pm
102 Views
Post# 36385050

Happy New Year!

Happy New Year!I believe this will be a very good year for Pharmala.   I had a few texts conversations with Nick. Strategically the high-net-worth investor can potentially bring many assets to the table for the company like additional cash flow if needed, knowledge and connections within the pharmaceutical industry and possibly other high-net-worth investors.  I believe the potential for news out of Europe is a high possibility in the new year, but of course Nick cannot comment on any specifics one way or the other and South America is considered a viable market for the company to expand into.  This does not mean they will, but Nick does see it as a potential market for the company.  Nick is quite tight-lipped on information, as he should be, and that gives me confidence in his integrity as the CEO to run this company honestly and with high expectations and standards.   
<< Previous
Bullboard Posts
Next >>